Adults were immunized with either baculovirus-expressed, purified recombinant hemagglutinin (rHA) from influenza AlBeijing/32/92 (H3N2) virus or saline placebo and evaluated for humoral and in vitro cellular immune responses. Compared with responses in placebo recipients, vaccinees had greater postvaccination H3Beijing/32 HA (H3)-specific lymphoproliferation and interleukin (IL)-2, IL-lO, and interferon-y (lFN-y) production. Mean increases in the production of IL-lO (~20 fold) and IL-2 (lO-fold) were relatively greater than that of IFN-y (4-fold) or IL-4 (no change). Serum H3 antibodies were induced in 80% of rHA recipients, and the rise in antibody titer was significantly correlated with changes in IL-2, IL-lO, and IFN-y concentrations. Vaccination with rHA only minimally enhanced anti-influenza virus cytotoxic T lymphocyte activity. These data demonstrate that rHA immunization of adults elicits a significant recall response by memory Band T lymphocytes and suggest that the cytokine response to vaccination has a T helper cell type 0-like profile.
Influenza viruses cause annual worldwide epidemics of respiratory illness that are associated with severe morbidity and mortality in susceptible persons. Influenza vaccines containing egg-grown, inactivated whole virus or subvirion components have been in widespread use for several decades and have a highly favorable record of performance. Field trials in healthy adults have demonstrated that licensed influenza vaccines are 60%-90% efficacious in preventing natural infection with antigenically well-matched strains of virus [1, 2] . Influenza vaccination also attenuates the severity of illness and reduces the incidence of life-threatening complications in persons who become infected [1, 3] . There nevertheless remains a concern that the protection conferred to at least some subsets of the population may be suboptimal, which has prompted investigation of the vaccine-and host-related factors that modulate protective immunity [4] .
Studies of influenza vaccine immunogenicity have traditionally focused on the induction of humoral responses. Neutralizing antibodies directed against the hemagglutinin (HA) surface glycoprotein of the virus are thought to have a predominantly prophylactic role in preventing infection [5] but also have a demonstrated capability to mediate virus clearance in the absence of other immune effector mechanisms [6] . Serum antibody titers quantified by hemagglutination inhibition (HAl) correlate well with virus-neutralizing activity and are the most widely used surrogate measure of inactivated influenza vaccine-induced protection [7] . When administered at the currently recommended dose of~15 f.tg of each HA antigen, licensed inactivated influenza vaccines elicit protective levels of serum HAl antibody in at least 90% of healthy adult recipients [1, 8] .
Much less is known about T cell-mediated immune responses to influenza vaccination. The potential relevance of cellular immunity to influenza virus has been highlighted by murine studies demonstrating that both CD8+ and CD4+ T lymphocytes recognize virus-infected cells, restrict viral replication in vivo, and promote the resolution of infection [9] [10] [11] [12] [13] [14] and also confer heterosubtypic immunity to primed hosts against viruses that are antigenically distinct from those encountered by earlier infection [15, 16] . Most of these reports have emphasized the effector role of cytotoxic T lymphocytes (CTL) in mediating virus clearance, and one study in humans has documented an inverse relationship between virus-specific memory CTL activity and nasal shedding of influenza virus following experimental challenge [17] . Other reports have focused on the immunoregulatory role of antiviral T lymphocytes by characterizing the T helper cell dependence of antibody and CTL responses [18] [19] [20] or by measuring in vivo cytokine expression following murine influenza virus infection [21] [22] [23] [24] [25] . Given the ability of cytokines to enhance or suppress both antigen-specific immune responses and nonspecific inflammatory responses, as well as their potential role as antiviral effector molecules [26] , an assessment of cytokine responses following influenza vaccination should provide insight into the mechanisms of vaccine protection and potential immunomodulatory strategies to improve vaccine immunogenicity and efficacy.
Recombinant DNA technology has allowed the cloning of the influenza virus RA gene, its expression in eukaryotic systems, and efficient purification of the protein product for use as a purified subunit vaccine. We recently reported that a vaccine containing baculovirus-expressed purified recombinant RA (rRA) from an influenza A (R3N2) virus was efficacious in preventing natural infection of young adults [27] . In this and other clinical trials of rRA vaccines to date, immunogenicity was evaluated only in terms of neutralizing RA-specific IgG antibody responses [27 -29] . The present investigation was undertaken to extend these findings, by characterizing in vitro cellular immune responses to rRA vaccination, and to assess whether these responses are correlated with vaccine-induced increases in serum antibody titers.
Materials and Methods
rHA preparation. The rHAs used in this study consisted of full-length uncleaved H3Beijing/32 HA (H3) and Hhexas/91 HA (HI) glycoproteins from influenza A1Beijing/32/92 (H3N2) and AI Texas/36/91 (HINI) viruses, respectively. EachrHA was produced in Sf9 (Spodoptera frugiperda) cell cultures following infection with a baculovirus vector containing a eDNA insert encoding the HA gene. The expressed protein was purified by low-pressure, lowtemperature ion-exchange chromatography under nondenaturing conditions to >99%, as measured by quantitative scanning densitometry of the bulk antigen electrophoresed on SDS-polyacrylamide gels. The identity of each rHA was confirmed by amino acid analysis, N-terminal sequencing, and Western blot analysis with antisera to influenza AlBeijing/32/92 (H3N2) or AlTexas/36/ 91 (HINI) virus. Bulk recombinant H3 (rH3) and rHI antigens were supplied as sterile solutions in PBS and were appropriately diluted in cell culture medium just before use in in vitro assays. The rHA vaccine contained 45 ,ug/dose of the rH3 antigen dissolved in PBS. This dose of rHA was used because it had previously been shown to stimulate serologic responses that were approximately equivalent to those elicited by licensed vaccine [28] .
Viruses. Influenza A/Beijing/32/92 (H3N2), AlTaiwan/1/86 (HINl), and B/Panama/45/90 viruses were propagated in IO-dayold embryonated eggs. Virus titers were quantitated by hemagglutination assay. Infectious stocks of allantoic fluid were stored frozen at -80°C before use.
Clinical studies. Fifty healthy adult volunteers 18-49 years old (mean ± SD, 32 ± 8) were enrolled. Subjects were randomly assigned to receive an intramuscular injection of either rH3 vaccine or saline placebo in a volume of 0.5 mL. The randomization sequence was prepared so that in each consecutive pair of volunteers, I was assigned to receive vaccine and the other placebo. Thirtyone of the participants were women. The mean age and sex ratio of subjects were comparable between vaccine groups. Vaccinations were done during late November and early December 1994. Serum and heparinized whole blood specimens were obtained at the time of vaccination and 3 weeks afterward. Blood was obtained from 4-6 persons on any given day. Specimens were processed in a blinded fashion. Serology. Serum HAl antibodies to influenza AlBeijing/32/92 (H3N2) and A/Texas/36/91 (HINl) whole virus antigens (CDC, Atlanta) were measured by a standard microtiter assay [30] , following removal of nonspecific inhibitors with receptor-destroying enzyme and of cold agglutinins by hemadsorption at 4°C. HA-specific IgG antibodies were measured by ELISA as described [31] , using purified rH3 or rHI as the coating antigen. Reciprocal antibody titers were logarithmically transformed for statistical analysis. A significant antibody response to immunization was defined as ã 4-fold rise in titer between the prevaccination and postvaccination serum specimens.
Cell separation. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized whole blood by density centrifugation in Accuspin tubes containing Histopaque (Sigma, St. Louis) and then washed three times in RPMI 1640 supplemented with 2 mML-glutamine, 100 U/mL penicillin, and 100 ,ug/mL streptomycin. Freshly isolated PBMC were used in all cell cultures.
Lymphoproliferation assay. For measurement of influenza virus HA-specific cell proliferative responses, PBMC cultures were established in 96-well flat-bottom plates by adding 10 5 cells/well to 200 ,uL of RPMI medium supplemented with 10% human AB gamma globulin-free serum. Cells were stimulated with 4 ,ug/mL of either rH3 or rHl antigen. These antigen concentrations were found to elicit optimal lymphoproliferative responses in preliminary experiments using PBMC obtained from persons with a history of recent influenza virus infection (data not shown). Control wells contained PBMC in medium without antigen. After 5 days of incubation at 37°C, individual wells were pulsed with 1 ,uCi of eH]thymidine for 18 h and then harvested onto glass fiber filters for radioassay by standard scintillation techniques. All assays were done in quadruplicate, and raw counts per minute from replicate wells were averaged. The antigen-specific response was expressed as a stimulation index (SI) calculated by dividing the mean counts per minute of antigen-containing wells by that of control wells.
Induction ofcytoldnes. PBMC cultures were established in 24-well flat-bottom plates by adding 1.5 x 10 6 cells/well to 1.5 mL of AIM V medium (Life Technologies GIBCO BRL, Gaithersburg, MD) containing 4 ,ug/mL of rH3 or rHl antigen. Control wells contained PBMC in medium without antigen. After cultures were incubated at 37°C for either 2 or 6 days, the supernatants from duplicate wells were harvested and pooled. Supernatants were cleared of cellular debris by centrifugation and stored at -20°C until assayed for cytokine levels. The time points chosen for harvesting culture supernatants were based on prior kinetic studies documenting the peak activities of specific cytokines in influenza virus-stimulated PBMC cultures (unpublished data).
IL-2 assay. Supernatants harvested on day 2 from PBMC cultures were assayed for interleukin (IL)-2 bioactivity using the IL-2-dependent MTL 2.8.2 cell line as described [32] . The assay was standardized using human recombinant IL-2 and had a minimal level of detection (MLD) of 1.0 U/mL. lID 1997; 175 (February)
IL-4, IL-IO, and interferon-v assays.
Commercially available ELISAs were used to quantify IL-4 (Biosource, Camarillo,CA), IL-10, and interferon-y (IFN-y) (INCSTAR, Stillwater, MN) concentrations in supernatants harvestedfrom 6-day PBMC cultures. For each cytokineassay,all supernatants weretestedconcurrently. The ELISAs had MLDs of 0.082 pglmL for IL-4, 2.36 pglmL for IL-IO, and 0.04 U/mL for IFN-y. In specimens with undetectable cytokine, the concentration was arbitrarily assigned a value of 50% of the MLD.
Induction of influenza virus-specific CTL. Methods used for the induction and assay of CTL activity were essentially as described [31] . In brief, PBMC responder cells (2 X 10 7 ) were cultured for 7 days in RPMI medium containing 10% human AB gamma globulin-free serum in the presence of autologous stimulator cells (5 X 10 6 ) that had been infected with~200 hemagglutinating units of influenza NBeijing (H3N2) virus. When sufficient numbers of cytolytic effector cells were available from the 7-day cultures, aliquots were depleted of CD4", CDS+, or CD56+ cells by direct immunomagnetic separation as described [33] using commercially available beads (PerSeptive Diagnostics, Cambridge, MA) coated with monoclonal antibodies to CD4, CDS, and CD56, respectively, or they were mock-depleted using beads coated with anti-mouse IgG. Using flow cytometric analysis, we have found that direct immunomagnetic negative selection routinely eliminates 90% of the targeted cell population. Cytotoxicity assay. Effector cells were tested for cytolytic activity by a standard 6-h [ 51Cr]chromium release assay using radiolabeled autologous phytohemagglutinin-activated lymphoblast targets that were either infected with influenza NBeijing (H3N2), NTaiwan (HINI), or B/Panama virus or mock-infected with allantoic fluid. Target cells (10 4 cells/well) were combined with equal volumes of autologous undepleted (i.e., not subjected to any immunomagnetic beading), CD4", CDS-, CD56-, or mock-depleted effector cells at various effector-to-target (E:T) ratios in round-bottom wells on 96-microwell plates. Control wells for determining the maximum and spontaneous release of radioactive label contained target cells together with 100 J.lL of 5% Tween 20 or complete medium, respectively. Percentage of specific lysis was calculated as [(E -S)/(M -S)] X 100, where E, M, and S represent the measured radioactivity in cell culture supernatants from experimental release, maximum release, and spontaneous release wells, respectively. Virus-specific lysis was calculated by subtracting the percentage of specific lysis of mock-infected targets from that of influenza A or B virus-infected targets. Spontaneous release averaged < 15% of maximum release throughout the study.
Statistical analyses.
Experimental results of continuous data are expressed for each group as the mean ± SE. Differences between groups were analyzed using Fisher's exact test to compare proportions and the unpaired Student's t test to compare postvaccination means of continuous data. Differences within groups between pre-and postvaccination data were analyzed using the paired Student's t test. The Spearman rank test was used to assess the nonparametric correlation between changes in antibody titers versus changes in either lymphoproliferation or cytokine production among rH3 vaccine recipients.
Results
Serologic responses to vaccination. Preexisting titers of serum antibody to the HA of influenza A1Beijing (H3N2) virus were relatively high among our volunteers (table 1) . About half of the subjects had baseline HAl titers~1:32, which is the level of antibody that is conventionally thought to correlate with protection from infection by homologous virus. Among subjects who were administered rH3 vaccine, titers of HAl antibody to H3 increased by at least 4-fold in 20 (80%) and by 3 weeks after vaccination were~1:32 in all 25. ELISA IgG HA antibody responses also occurred in 80% of rHA vaccinees. Mean postvaccination titers of HAl and ELISA IgG HA antibody to H3 were significantly higher in the vaccine group than they were in the placebo group (P < .001 in both cases, Student's t test). Parallel assays performed with HI antigen demonstrated~4-fold HAl and ELISA IgG HA antibody titer rises in 5 (20%) and 3 (12%), respectively, of the rH3-vaccinated subjects. The same subjects had increases ranging from 64-fold to 4096-fold in their titers of serum HAl antibody to A1Beijing (H3N2) virus.
Lymphoproliferation responses to vaccination. Immunization with rH3 vaccine resulted in a marked enhancement of the in vitro lymphoproliferative response to H3 and a modest enhancement of the response to HI (figure 1). Compared to persons who received placebo, rH3-vaccinated subjects had significantly higher postvaccination mean SIs to both H3 (P < .002, Student's t test) and HI (P < .05, Student's t test)
antigens. As expected, there was no change in the mean SIs of PBMC from placebo recipients.
The H3-specific lymphoproliferative response to immunization, calculated as the difference in SI from before to after vaccination, tended to increase in direct relation to the rise in serum HAl antibody titer (figure 2), although the correlation was not quite statistically significant (r = .379, P = .062, Spearman's rank test). Furthermore, 3 of the 5 vaccinees who demonstrated a~4 fold rise in antibody titer to HI had an increase of~1.0 in their SI to this antigen, compared with only 4 of the 20 serologic nonresponders (P = .075, Fisher's exact test).
Cytokine responses to vaccination. Cytokine concentrations measured in PBMC culture supernatants generally paralleled lymphoproliferative activity with respect to differences between vaccine and placebo groups, pre-versus postvaccination time points, and the rHAs used for in vitro stimulation (figure 3). The H3 specificity of these responses was confirmed by the absence of corresponding changes in parallel cultures stimulated with HI. Antigen-stimulated concentrations of IL-2, IL-4, and IFN-y were usually greater than the MLDs for the respective assays, whereas those of IL-I 0 were frequently undetectable, particularly in cultures ofPBMC obtained before vaccination. Disproportionate increases in the production of the different cytokines were detected in H3-stimulated cultures following immunization with rH3 vaccine. The IL-IO response was the most striking, with mean levels of this cytokine rising by , . . . . . , 20-fold (this may be an underestimate, since prevaccination levels of IL-IO were frequently below the MLD). In contrast, there was a l G-fold mean increase in IL-2, a 4-fold mean increase in IFN-y, and essentially no change in IL-4. Three weeks after immunization, H3-stimulated cultures from vaccinated subjects had significantly higher concentrations oflL-2 (P < .001, Student's t test), IL-IO (P < . 
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• Vaccine 0 Placebo err responses to vaccination. After 7 days of in vitro stimulation with influenza A (H3N2) virus-infected autologous cells, PBMC effectors were assayed for cytolytic activity using virus-infected autologous lymphoblasts as targets. Each population of effector cells was tested against a panel of targets that had been infected with either influenza A (H3N2), influenza A (HINl), or influenza B virus. To further characterize the cytolytic effectors, we performed parallel assays in a subset of specimens using effector populations from which CD4+, CD8+, or CD56+ cells had been selectively depleted by immunomagnetic beading. As shown in table 2, effector cells exhibited cross-reactive recognition of targets infected with either (H3N2) or (HINl) subtype of influenza A virus but had diminished activity against influenza B virus-infected targets. The cytotoxicity was largely accounted for by CD8 + cells, since the lysis of all targets was substantially reduced by depletion ofthis cell subset but was not appreciably changed by depletion of CD4+ or CD56+ subsets. CTL responses to vaccination were relatively limited. There was a small but statistically significant increase in cytotoxicity at one or more E:T ratios against targets infected with all three subtypes (i.e., H3N2, HINl, and B) of influenza virus following rH3 vaccination, whereas no significant changes were seen in the placebo group (table 3) . The postvaccination mean virus-specific lysis of H3N2 (P < .01, Student's t test) as well as HINI (P < .05, Student's t test) influenza A virusinfected targets was higher in rH3 vaccine recipients than in placebo controls when comparing the data at an E:T ratio of 10:1 but not at other E:T ratios.
Discussion
The principal objective of this study was to determine what kinds of cellular immune responses are stimulated by vaccination with purified rHA from influenza virus. Given that both H3N2 and HINI subtypes of influenza A virus have been in circulation for the past 2-3 decades, and that primary influenza virus infection in humans tends to occur during childhood, it can be assumed that most adults are immunologically primed to mount secondary responses on reexposure to either of these subtypes of HA antigen. Cellular immune responses that are detected following in vitro stimulation of adult PBMC with H3 or HI thus reflect the activity of memory lymphocytes and can be used to monitor the effects of vaccination on a variety ofmemory T cell functions. It must be acknowledged, however, that the in vitro activity of circulating memory lymphocytes may not be a reliable surrogate of in vivo responses in lymphoid organs or at tissue sites where infection is localized.
A number of previously published reports have documented the ability of inactivated influenza vaccines containing egggrown whole virus or subvirion components to enhance in vitro antigen-specific cell proliferation, cytokine production, or CTL Antibody Titer (1092 fold-rise) activity in adult subjects [31, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . Unlike the present study, none of these earlier investigations evaluated all of these immune parameters simultaneously or included placebo recipients as controls. The documentation of a cellular immune response to influenza vaccine has thus relied on paired data analysis Table 2 . Specificity and phenotypic characterization of cytolytic effectors from influenza A (H3N2) virus-stimulated peripheral blood mononuclear cell cultures.
% specific lysis (mean ± SE) of autologous targets infected with
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Mock-depleted 23.3 ± 2.7 20.S ± 2.4 7.5 ± 1.2 CD4-19.7 ± 2.4 lS.2 ± 1.9 6.1 ± 0.9 CDS-9.S ± 1.5 7.7 ± 1.4 2.3 ± 0.9 CD56-22.4 ± 3.3 15.6 ± 2.0 S.6 ± 1.2 NOTE. Effector cells were depletedof specificcell subsets by direct immunomagnetic negative selection using beads coated with anti-CD4, anti-CDS, or anti-CD56 or they were mock-depletedusing beads coated with anti-mouse IgG. Results shown are from assays done at effector-to-target ratio of 40:1 using effectors obtained before vaccination from 22 persons. comparing measurements obtained from the same persons before and after vaccination. A problem with this approach is that unless assays are simultaneously performed using cryopreserved PBMC (which was not the case in the studies referenced above), longitudinal changes in cellular immune activity may be influenced by variability in laboratory conditions related to observer bias. Furthermore, biologic fluctuations in peripheral blood T cell activity can occur over time, even in the absence of any intervening immunizing event. By including a placebo group and using a randomized, double-blind study design, we controlled for both biologic variability and interassay variability as potential sources of bias.
The present data clearly demonstrate that rH3 vaccination elicited secondary in vitro cellular immune responses to H3. There is a theoretical possibility that contaminating proteins derived from the baculovirus vector or Lepidopteran host cell were also target antigens responsible for the enhanced in vitro responses among vaccinated subjects, but this seems unlikely given the >99% purity of the rHA preparations used for these studies. The modest but significant increase of lymphoproliferation in HI-stimulated cultures following rH3 vaccination may be explained on the basis of cross-reactive epitopes shared by antigenically conserved portions of the respective H3 and HI proteins. It is not surprising that the lymphoproliferative response demonstrated at least a limited degree ofheterosubtypic cross-reactivity, because human CD4+ T cell recognition of influenza virus HA is thought to be dominated by the recognition of highly conserved epitopes [46] . A similar mechanism, involving recognition of cross-reactive HA epitopes by memory T helper cells, memory B cells, or both, may also account for the induction of antibodies to HI that occurred in a minority of the rH3 vaccine recipients. Other investigators have also observed heterosubtypic antibody responses in a subset of volunteers following immunization with monovalent rH3 or rHl vaccine [29] .
Published data are extremely limited regarding the HA subtype specificity of in vitro lymphoproliferative responses following human immunization with egg-grown inactivated whole virus or subvirion influenza vaccine. The major reason for this is that clinical studies ofcellular immune responses to influenza vaccine have almost always used either bivalent or trivalent preparations containing more than one HA subtype. Furthermore, lymphoproliferative responses elicited by conventional vaccines (even if monovalent) may be at least partially accounted for by the presence of viral neuraminidase (NA) and internal proteins in addition to HA, unless in vitro assays are done using either purified HA antigen or subunit HA-NA antigen containing an NA distinct from those encountered by prior exposure. We are aware of only one published report in which volunteers (children) were immunized with monovalent inactivated influenza vaccines and subsequently evaluated for in vitro lymphoproliferative responses to purified reassortant viruses containing homologous and heterologous HA and NA antigens [35] . In agreement with our data, these investigators found that vaccination elicited lymphoproliferative responses that for the most part were HA or NA subtype-specific, although the numbers of subjects studied (5 in one vac~ine group and 4 in another) may have been too small to detect subtle or infrequent heterosubtypic responses.
There is also a paucity of information regarding human cytokine responses to influenza virus infection or vaccination. Studies to date have focused almost exclusively on IL-2 or IFN-y production by antigen-stimulated PBMC following immunization with either inactivated [39] [40] [41] [42] [43] or live attenuated [47] [48] [49] (Gorse GI, Powers DC, unpublished data) influenza virus vaccines. The vaccine enhancement ofIL-lO production represents a novel finding and is noteworthy in light of the ability of this cytokine to inhibit IL-2 and IFN-y secretion and to down-regulate a number of other immune phenomena, including antigen-specific T cell proliferation [50, 51] . On the other hand, IL-lO stimulates immunoglobulin production by B cells [52] and is therefore likely to promote humoral responses following immunization. We found that serologic responses to vaccination were significantly correlated with changes in the in vitro concentration of IL-2, IL-10, and IFN-y but not of IL-4. Further investigation is needed to more clearly define the cross-regulatory interactions between these and other cytokines and their relevance to vaccine-induced immunity.
Since bulk PBMC cultures were used for lymphoproliferation and cytokine assays, the identities and relative contributions of specific cell subsets within the responder cell populations were not defined. All of the cytokines that were measured can be produced by both CD4+ and CDS+ T lymphocytes, although the use of purified peptide antigen rather than live virus as the in vitro stimulus for these assays would be expected to preferentially bias for CD4+ T cell responses [53] . Activated B cells are also a source ofIL-l 0 [54] and may have contributed to the vaccine-enhanced production of this cytokine. We are currently developing the immunocytochemical techniques to resolve these uncertainties.
The enhancement of influenza virus-specific CD8+ CTL activity among rH3-vaccinated subjects was quite limited compared with the lymphoproliferative and cytokine responses. This contrast may reflect the preferential activation of CD4+ rather than CD8+ T cells that is to be expected with a subunit vaccine, given the inefficiency with which purified peptides enter the endogenous pathway of antigen processing for major histocompatibility complex (MHC) class I presentation [53] . Furthermore, no HA epitopes have been identified as target antigens for human influenza virus-specific class I-restricted CTL [55] . The limited CTL response to vaccination may simply be a "bystander" effect of increased cytokine production following in vivo processing and MHC class II presentation of nonreplicating antigen to CD4+ memory lymphocytes. When present at sufficiently high local concentrations, cytokines may activate resting memory CTL precursors in the absence of class I antigen presentation [56, 57] .
The polarization of CD4+ T helper cell activity into distinct T helper cell type 1 (Thl) and Th2 profiles based on patterns of cytokine secretion has become a useful paradigm for understanding host immune responses to a number of infectious pathogens [58] . Thl cells secrete IL-2 and IFN-'}' , mediate delayed-type hypersensitivity, and preferentially enhance CTL activity, whereas Th2 cells secrete IL-4, IL-5, IL-6, and IL-10 and provide efficient help for antibody production. Other cytokine patterns have also been described, including the ThO profile, which includes both Thl and Th2 cytokines [59] . The relative extent to which Thl-versus Th2-like responses contribute to protective immunity against influenza virus have not been clearly defined. In a murine influenza model, adoptively transferred antiviral CD4+ Thl clones have been shown to be protective against lethal challenge, whereas CD4+ Th2 clones are nonprotective and possibly associated with disease enhancement [60] . On the other hand, the observation that influenza virus infection in mice induces the concurrent production and mRNA expression of IL-2, IL-l 0, and IFN-'}' suggests that the in vivo cytokine response to this virus cannot be rigidly categorized on the basis of a Thl or Th2 phenotype and most likely comprises a balance between the two [22] [23] [24] .
To our knowledge, this is the first published report to assess the relative production of Thl-and Th2-like cytokines in humans following influenza immunization. Since cytokines belonging to both subsets were elicited, the overall response to rHA vaccine is perhaps most accurately considered as ThO in character. Definitive conclusions regarding the Thl/Th2 phenotype of the vaccine response may ultimately require analysis of cytokine production at the single cell or clonal level, but these types of studies are probably not feasible for clinical trials involving dozens of volunteers. Investigations are underway to extend our present findings by measuring the induction of other cytokines and by comparing these responses with those elicited by alternative vaccines containing inactivated or live attenuated influenza virus components as well as to those that occur in specific high-risk populations.
It remains unclear whether and to what extent the cytokine profile and associated immune phenotype of a memory response to influenza vaccination in primed hosts can be altered by the nature of the vaccine or the use of immunomodulators. A number of studies have suggested that the Thl/Th2 character of memory cells is largely determined by the conditions present at the time of primary immunization [61, 62] , although there also evidence of at least some plasticity in the recall response [63] . There is, nonetheless, a theoretical concern that repetitive immunization with inactivated virus or subunit preparations, as occurs on an annual basis in high-risk groups targeted to receive influenza vaccine, may progressively skew the T cell memory response toward a less favorable profile. Despite the demonstrated efficacy of inactivated influenza vaccines containing egg-grown or recombinant protein antigens, optimal protection against this virus will likely require an immunization strategy designed to stimulate humoral, cellular, and mucosal immunity in a manner that most closely mimics the response to natural infection.
